Turpie A G
HGH-McMaster Clinic, Hamilton General Hospital, ON, Canada.
Haemostasis. 1996 Oct;26 Suppl 4:220-6. doi: 10.1159/000217302.
Antithrombotic therapy is mandatory in most patients with venous thrombosis. The results of randomized trials have established the requirement for initial treatment with heparin and have determined the optimal anticoagulant regimen for secondary prophylaxis. Recent studies have demonstrated that low molecular weight heparins, that have improved pharmacologic and pharmacokinetic properties over standard heparin, are effective and safe in the treatment of deep vein thrombosis. Two large randomized clinical trials have shown the feasibility of the outpatient treatment of patients with acute deep vein thrombosis with low molecular weight heparins. Home therapy will result in improved clinical utility of anticoagulant treatment and in cost savings.
对于大多数静脉血栓形成患者而言，抗栓治疗必不可少。随机试验结果已明确了肝素初始治疗的必要性，并确定了二级预防的最佳抗凝方案。近期研究表明，与标准肝素相比，具有更优药理学和药代动力学特性的低分子量肝素在治疗深静脉血栓形成方面有效且安全。两项大型随机临床试验已证明，使用低分子量肝素对急性深静脉血栓形成患者进行门诊治疗是可行的。家庭治疗将提高抗凝治疗的临床效用并节省费用。
